Renovaro announced that it will change its corporate name to “Lunai Bioworks” to better reflect its strategic direction and growing expertise in AI-powered biodefense, drug discovery and advanced diagnostics. The new name underscores the company’s commitment to harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. The name change was approved by the Board of Directors, and the company’s common stock will continue to trade on Nasdaq under its current ticker symbol, RENB, until further notice.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RENB:
- Renovaro Biosciences Granted Nasdaq Compliance Extension
- Renovaro BioSciences secures multiple U.S. patents in biomedical AI
- Renovaro Biosciences Chairman Announces Resignation
- Renovaro BioSciences announces publication of study on dendritic cell therapy
- Renovaro Biosciences Receives Nasdaq Compliance Notice